|
|
Volumn 344, Issue , 2012, Pages
|
|
Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
DRUG INDUSTRY;
ECONOMICS;
EXUDATIVE MACULAR DEGENERATION;
HUMAN;
LEGAL ASPECT;
NOTE;
OFF LABEL DRUG USE;
UNITED KINGDOM;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DRUG INDUSTRY;
ENGLAND;
HUMANS;
OFF-LABEL USE;
WET MACULAR DEGENERATION;
|
|
EID: 84860647102
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.e2959 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
